Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2020-10-23 Major Shareholding Noti…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
SRIW_BONE THERAPEUTICS_TR-1_2020-10-16.pdf
Major Shareholding Notification Classification · 99% confidence The document is a formal notification, structured in tables with numbered sections (1 through 12), detailing changes in share ownership ('Acquisition ou cession de titres conférant le droit de vote'). It specifically mentions thresholds being crossed ('Seuil franchi (en %)') and lists the number of voting rights before and after a transaction for specific entities (SRIW SA, SOFIPOLE SA). This content directly corresponds to regulatory filings concerning insider transactions or major shareholding changes. Given the focus on director/executive transactions or significant ownership changes, the most fitting category is 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ). Since the notification explicitly details the change in voting rights percentage (9.30%) and names the entities involved in the transaction/holding, it strongly aligns with a Major Shareholding Notification (MRQ), which covers crossing ownership thresholds. It is not a general regulatory filing (RNS) because it is highly specific, nor is it a Director's Dealing (DIRS) unless the entities listed are directors themselves, but the structure points to a formal threshold notification.
2020-10-23 French
PR_2020-10-23_BOTHE_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information on the total number of voting rights and shares" and is dated October 23, 2020. It explicitly states that the information is published in accordance with Article 15 of the Belgian Law on the publication of major shareholdings. The content details the change in the total number of shares and voting rights due to a recent issuance following bond conversion. This type of mandatory disclosure regarding changes in the total share count (the denominator for major shareholding notifications) is a specific regulatory filing. While it relates to share capital changes, the primary focus is the official notification of the new total share count, which is often required in conjunction with major shareholding reports or as a standalone regulatory update. Given the options, this is a specific regulatory announcement concerning share structure changes, which aligns best with either 'SHA' (Share Issue/Capital Change) or 'RNS' (Regulatory Filings - general). Since it is a formal announcement detailing the exact number of shares and voting rights, it is a direct notification of a capital structure event. The most precise fit among the provided codes for a notification detailing the total number of shares and voting rights is 'SHA' (Share Issue/Capital Change), as the change was caused by a share issuance/conversion. However, since the core purpose is the mandatory disclosure of the new denominator, it is also a strong candidate for a general regulatory filing (RNS). Given the specific nature of the data (total shares/voting rights after an issuance), SHA is slightly more specific than RNS, but the context is a mandatory disclosure under Belgian law, making it a regulatory filing. Let's re-evaluate: The document announces the *result* of a share issuance/conversion and provides the new total share count. This is a direct update to the capital structure. Therefore, SHA (Share Issue/Capital Change) is the most appropriate classification for the substance of the announcement, even though it is presented as a press release/regulated information.
2020-10-23 English
PR_2020-10-23_BOTHE_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE" (Press Release - Regulated Information) dated October 23, 2020. The core content details an 'Information relative au nombre total de droits de vote et d'actions' (Information relating to the total number of voting rights and shares). It reports the issuance of new shares due to the conversion of convertible bonds and provides updated share counts, which directly relates to capital structure changes and significant share ownership reporting requirements (as referenced by Article 15 of the Belgian law mentioned). This content strongly aligns with announcements regarding capital structure changes or major shareholding notifications. Since it details the issuance of new shares resulting from financing conversions, the most specific category is 'Capital/Financing Update' (CAP). While it touches upon share counts (MRQ), the context is the direct result of a financing event (conversion of OCs), making CAP more appropriate than MRQ, which usually covers changes in ownership thresholds by external parties. It is not a full financial report (10-K, IR) or a simple dividend notice (DIV).
2020-10-23 French
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE - REGULATED INFORMATION" dated October 20, 2020. It provides an update on the recruitment status of a Phase III clinical study (JTA-004) for knee osteoarthritis, including expected timelines for results. This type of announcement, which communicates key operational and clinical progress outside of a formal periodic report (like 10-K or IR), fits best under the general category for regulatory announcements or press releases that don't match a more specific financial event code (like DIV, CAP, or ER). Since it is a general update and not a formal financial report, and it is explicitly marked as regulated information, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such official, non-standardized announcements.
2020-10-20 English
Bone Therapeutics a traité 50% des patients dans son étude pivot de Phase III évaluant le JTA-004 dans l’arthrose du genou
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) dated October 20, 2020. It provides an operational update regarding patient recruitment milestones in a Phase III clinical trial (JTA-004 for knee osteoarthritis) and reiterates expected timelines for results. This type of announcement, detailing operational progress, clinical trial status, or key business updates outside of mandated periodic financial reports (like 10-K or IR), is typically classified as a general regulatory announcement or press release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific notice like dividend declaration (DIV) or management change (MANG), the most appropriate general category for a regulated press release containing operational news is Regulatory Filings (RNS). It is not an announcement of a report publication (RPA) because it contains substantive news, not just a notice that a report is available.
2020-10-20 French
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
Regulatory Filings Classification · 98% confidence The document is explicitly titled "PRESS RELEASE - REGULATED INFORMATION" and dated October 5, 2020. The content details a significant business transaction: an exclusive license agreement between Bone Therapeutics, Link Health, and Pregene regarding the commercialization of the ALLOB cell therapy platform in Asia. This type of announcement, detailing strategic partnerships, financial terms (€55 million in payments, royalties), and business development, is characteristic of a corporate announcement intended for immediate public disclosure, often falling under general regulatory news. Since it is not a full financial report (10-K, IR), an earnings release (ER), a proxy statement (DEF 14A), or a specific capital change (CAP, SHA), the most appropriate classification is the general regulatory announcement category, RNS, as it is a formal, regulated press release about a material event.
2020-10-05 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.